LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 101

Search options

  1. Book ; Online: Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer

    Golubovskaya, Vita

    2023  

    Keywords Medicine ; Oncology ; cell therapy ; bispecific antibody ; chimeric antigen receptor ; cancer ; immunotherapy ; vaccine
    Language English
    Size 1 electronic resource (194 pages)
    Publisher MDPI - Multidisciplinary Digital Publishing Institute
    Publishing place Basel
    Document type Book ; Online
    Note English
    HBZ-ID HT030645972
    ISBN 9783036595672 ; 3036595678
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Book ; Online: Immunotherapy, tumor microenvironment and survival signaling

    Golubovskaya, Vita

    2022  

    Author's details edited by Vita Golubovskaya
    Language English
    Size 1 Online-Ressource (xi, 360 Seiten), Illustrationen, Diagramme
    Publisher MDPI
    Publishing place Basel
    Publishing country Switzerland
    Document type Book ; Online
    Note printed edition of special issue published in "Cancers" ; Open Access
    HBZ-ID HT021477847
    ISBN 978-3-0365-4420-5 ; 9783036544199 ; 3-0365-4420-8 ; 3036544194
    DOI 10.3390/books978-3-0365-4420-5
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Book ; Online: Immunotherapy, Tumor Microenvironment and Survival Signaling

    Golubovskaya, Vita

    2022  

    Keywords Medicine ; Clinical & internal medicine ; Autophagy ; colorectal cancer ; immunotherapy ; tumor stroma ; tumor microenvironment ; immune checkpoint inhibitors ; chemotherapy ; tyrosine kinase inhibitors ; angiogenesis ; check point inhibitors ; programmed cell death protein 1 ; programmed cell death 1 ligand 1 ; cardiotoxicity ; lung metastasis ; CAR-T ; hypoxia ; tumor ; microenvironment ; CD19 ; BCMA ; cancer ; melanoma ; immune escape ; antigen loss ; chimeric antigen receptor ; electroporation ; lentivirus ; lentiviral transduction ; macrophages ; leukemia cells ; lytic peptides ; targeted therapy ; dendritic cells ; pathogenesis ; risk factors ; breast cancer ; resistance ; checkpoint ; targeted treatment ; personalized medicine ; pediatric solid tumors ; chimeric antigen receptors ; cancer vaccines ; oncolytic viral therapy ; immunomodulation ; DCLK1 ; tumor stem cells ; clonogenicity ; mitochondria ; mitochondrial transfer ; tunneling nanotubes ; triple-negative breast cancer ; immune checkpoint inhibitor ; combination therapy ; cancer nanomedicine ; tumor antigens ; cancer metabolism ; cancer immunotherapy ; nanoparticles ; immunotherapeutic agent ; immunomodulators ; tuft cells ; cancer stem cells ; immunotherapies ; myeloid-derived suppressor cells ; regulatory T cells ; crosstalk ; tumor immune evasion ; cell-cell contact ; β2 integrins ; CD18 ; CD11 ; CAR-T cells ; CD37 ; cell therapy ; tumor antigen ; lymphoma ; CAR macrophage ; CAR T cell ; solid tumors ; immunometabolism ; miRNA ; immunogenic cell death ; n/a
    Language 0|e
    Size 1 electronic resource (376 pages)
    Publisher MDPI - Multidisciplinary Digital Publishing Institute
    Publishing place Basel
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021619351
    ISBN 9783036544205 ; 3036544208
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Editorial on "Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer".

    Golubovskaya, Vita

    Cancers

    2023  Volume 15, Issue 20

    Abstract: This Special Issue ... ...

    Abstract This Special Issue in
    Language English
    Publishing date 2023-10-19
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15205053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: CAR-T Cells Targeting Immune Checkpoint Pathway Players.

    Golubovskaya, Vita

    Frontiers in bioscience (Landmark edition)

    2022  Volume 27, Issue 4, Page(s) 121

    Abstract: CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, ... ...

    Abstract CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.
    MeSH term(s) Humans ; Immunotherapy ; Immunotherapy, Adoptive ; Neoplasms/metabolism ; Signal Transduction ; T-Lymphocytes
    Language English
    Publishing date 2022-04-18
    Publishing country Singapore
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2704569-9
    ISSN 2768-6698 ; 2768-6698
    ISSN (online) 2768-6698
    ISSN 2768-6698
    DOI 10.31083/j.fbl2704121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: CAR-T Cells Targeting Immune Checkpoint Pathway Players

    Vita Golubovskaya

    Frontiers in Bioscience-Landmark, Vol 27, Iss 4, p

    2022  Volume 121

    Abstract: CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, ... ...

    Abstract CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.
    Keywords car-t cell ; tumor ; checkpoint ; immunotherapy ; review ; Biochemistry ; QD415-436 ; Biology (General) ; QH301-705.5
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher IMR Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".

    Golubovskaya, Vita

    Cancers

    2021  Volume 14, Issue 1

    Abstract: Recently, novel types of immunotherapies such as CAR-T cell therapy demonstrated efficacy in leukemia, lymphoma, and multiple myeloma [ ... ]. ...

    Abstract Recently, novel types of immunotherapies such as CAR-T cell therapy demonstrated efficacy in leukemia, lymphoma, and multiple myeloma [...].
    Language English
    Publishing date 2021-12-24
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14010091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Cancer Immunotherapy: Where Next?

    Bodmer, Walter / Golubovskaya, Vita

    Cancers

    2023  Volume 15, Issue 8

    Abstract: The fundamental problem of dealing with cancer is that cancer cells are so like normal cells that it is very hard to find differences that can be a basis for treatment without severe side effects. The key to successful cancer immunotherapy will be based ... ...

    Abstract The fundamental problem of dealing with cancer is that cancer cells are so like normal cells that it is very hard to find differences that can be a basis for treatment without severe side effects. The key to successful cancer immunotherapy will be based on a very careful choice of cancer targets that are sufficiently cancer specific not to cause serious side effects. There are two fundamentally different ways to deploy the immune system for such cancer treatments. One is to increase the efficacy of the cancer patient's own immune system so that it attacks these differences. This has been achieved by "checkpoint blocking" which is very successful but only with a relatively small proportion of cancers. Secondly, one can produce antibodies, or T cells, whose specificity is directed against proteins expressed differentially in cancers. CART cell treatments have proved very effective for some blood cancers but not so far for common solid tumours. Humanised, unmodified monoclonal antibodies have been used extensively for the treatment of certain adenocarcinomas with modest success. However, using antibodies together with the body's own immune system to treat cancers by engineering monoclonal antibodies that are directed at both a target antigen on the cancer cell surface and also against T cells shows promise for the development of novel immunotherapies. Genes can be found which are expressed highly in some cancers but with a low or absent expression on normal tissues and so are good novel targets. It is so far, only immune-based killing that can kill bystander target negative cells, which is essential for successful treatment since hardly ever will all the cells in a cancer express any desired target. We conclude that, while there still may be many hurdles in the way, engineered bispecific T cell attracting monoclonal antibody-mediated killing of cancer cells may be the most promising approach for achieving novel effective cancer immunotherapies.
    Language English
    Publishing date 2023-04-18
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15082358
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers.

    Sureban, Sripathi M / Golubovskaya, Vita

    Frontiers in oncology

    2022  Volume 12, Page(s) 1043615

    Language English
    Publishing date 2022-10-24
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.1043615
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: CAR-T Cell Therapy: From the Bench to the Bedside.

    Golubovskaya, Vita

    Cancers

    2017  Volume 9, Issue 11

    Abstract: CAR (Chimeric Antigen receptor)-T cell therapy is a novel type of therapy that uses engineered T cells with an antibody single-chain variable fragment (ScFv) extracellular domain that binds tumor-associated antigens[ ... ]. ...

    Abstract CAR (Chimeric Antigen receptor)-T cell therapy is a novel type of therapy that uses engineered T cells with an antibody single-chain variable fragment (ScFv) extracellular domain that binds tumor-associated antigens[...].
    Language English
    Publishing date 2017-10-31
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers9110150
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top